Oruka Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Oruka Therapeutics (Nasdaq: ORKA) will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco from January 12-15, 2026. Oruka's presentation is scheduled for Thursday, January 15, 2026 at 9:00 AM PT. A live webcast and replay will be available on the company's investor events website.

The company is a clinical-stage biotechnology firm developing novel biologics for chronic skin diseases including plaque psoriasis. Investors can access the webcast and replay via Oruka's investor events page.

Key Figures

Conference dates January 12–15, 2026 44th Annual J.P. Morgan Healthcare Conference schedule

Company presentation date January 15, 2026 Scheduled Oruka presentation at J.P. Morgan conference

Presentation time 9:00 AM PT Oruka J.P. Morgan Healthcare Conference session time

Market Reality Check

$27.81 Last Close

Volume Volume 866,623 is 21% above the 20-day average of 717,472. normal

Technical Price 26.88 is trading above the 200-day MA at 17.64.

Peers on Argus

ORKA was down 4.92% pre-news while peers were mixed: SVRA up 2.84%, BCAX down 1.83%, ANAB down 2.94%, PVLA down 11.9%, RZLT down 8.6%, indicating stock-specific dynamics rather than a uniform sector move.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Dec 11	Board change	Neutral	-0.1%	Director resignation and appointment of Christopher Martin to board roles.
Nov 12	Earnings update	Positive	+0.3%	Q3 2025 results with strong cash position and clinical progress timelines.
Oct 29	Investor conferences	Neutral	+0.6%	Multiple November 2025 investor conference presentations on pipeline programs.
Sep 17	Private placement	Positive	+8.8%	$180M PIPE financing to fund R&D, corporate expenses, and working capital.
Sep 17	Clinical data	Positive	+8.8%	Positive interim Phase 1 results for ORKA-001 in plaque psoriasis.

Pattern Detected

Recent news events, including financing, clinical data, and governance updates, have generally seen price reactions that align directionally with the underlying news tone, with no clear pattern of contrarian moves.

Recent Company History

This announcement continues Oruka’s pattern of visibility-building events following key 2025 milestones. Positive interim Phase 1 data for ORKA-001 and a $180M PIPE on Sep 17, 2025 supported development of EVERLAST-A and EVERLAST-B trials. Q3 2025 results on Nov 12, 2025 highlighted a cash position of $500.9M and advancing Phase 1/2 programs. Governance changes on Dec 11, 2025 added commercial expertise to the board. Today’s J.P. Morgan conference appearance fits the ongoing investor outreach and clinical pipeline communication strategy.

Regulatory & Risk Context

Active S-3 Shelf Registration 2025-10-14

An active Form S-3/A resale registration filed on Oct 14, 2025 covers up to 39,425,806 shares of common stock for potential resale by existing stockholders. The company is not selling shares in this registration and will not receive proceeds from these resales, other than nominal cash if pre-funded warrants are exercised. The registered resale shares represent a significant portion of outstanding shares, which may influence secondary-market supply depending on selling stockholder activity.

Market Pulse Summary

This announcement highlights Oruka’s participation in the 44th Annual J.P. Morgan Healthcare Conference, with a presentation on January 15, 2026 at 9:00 AM PT. It continues a pattern of active investor outreach following positive ORKA-001 Phase 1 data, a $180M PIPE, and strong $500.9M liquidity as of Q3 2025. Investors may watch for any updates shared at the conference on clinical timelines, use of prior financing proceeds, and how existing resale registrations might interact with future capital needs.

Key Terms

biologics medical

"a clinical stage biotechnology company developing novel biologics designed to set a new standard"

Biologics are medicines made from living cells or their components rather than from simple chemical recipes, more like a handcrafted product than a mass-produced pill. They matter to investors because they often command higher prices and longer patent protection but also carry greater manufacturing, regulatory and supply risks—so a successful biologic can boost a company’s revenue significantly, while setbacks can quickly affect its stock.

plaque psoriasis medical

"for the treatment of chronic skin diseases including plaque psoriasis, today announced that the Company"

A chronic autoimmune skin condition that causes raised, red, scaly patches where the skin sheds too quickly, like a tree producing bark in clumps instead of renewing smoothly. It matters to investors because prevalence, severity, and treatment options drive demand for therapies, shape clinical trial design and regulatory review, and affect potential market size, pricing and reimbursement for drugs or devices aimed at relieving symptoms or altering the underlying immune response.

AI-generated analysis. Not financial advice.

MENLO PARK, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced that the Company will present at the 44th Annual J.P. Morgan Healthcare Conference, taking place in San Francisco, CA from January 12-15, 2026.

Presentation Details
Date: Thursday, January 15^th, 2026
Time: 9:00 AM PT

A webcast and replay of Oruka’s presentation will be available on the Oruka investor events website at https://ir.orukatx.com/news-events/events-presentations.

About Oruka Therapeutics

Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka’s mission is to offer patients suffering from chronic skin diseases like plaque psoriasis the greatest possible freedom from their condition by achieving high rates of complete disease clearance with dosing as infrequently as once or twice a year. Oruka is advancing a proprietary portfolio of potentially best-in-class antibodies that were engineered by Paragon Therapeutics and target the core mechanisms underlying plaque psoriasis and other dermatologic and inflammatory diseases. For more information, visit www.orukatx.com and follow Oruka on LinkedIn.

Investor Contact: 
Alan Lada 
(650)-606-7911 
alan.lada@orukatx.com 

FAQ

When will Oruka Therapeutics (ORKA) present at the J.P. Morgan Healthcare Conference?

Oruka will present on January 15, 2026 at 9:00 AM PT during the conference running January 12-15, 2026.

How can investors watch Oruka Therapeutics (ORKA) presentation at JP Morgan?

A live webcast and replay will be available on Oruka's investor events website at https://ir.orukatx.com/news-events/events-presentations.

What will Oruka Therapeutics (ORKA) discuss at the January 15, 2026 presentation?

The company will present updates on its clinical-stage biologics program for chronic skin diseases, including plaque psoriasis.

Is the Oruka (ORKA) JP Morgan presentation open to the public?

Yes, the presentation will be webcast publicly and a replay will be posted on the investor events page.

Why is Oruka Therapeutics (ORKA) presenting at the 44th Annual J.P. Morgan Healthcare Conference important for investors?

Presenting at the conference provides investors an opportunity to hear corporate updates on clinical progress and strategic priorities directly from management.

Where and when is the 44th Annual J.P. Morgan Healthcare Conference taking place?

The conference takes place in San Francisco, CA from January 12-15, 2026, with Oruka's presentation on January 15.